<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545582</url>
  </required_header>
  <id_info>
    <org_study_id>C-05</org_study_id>
    <nct_id>NCT02545582</nct_id>
  </id_info>
  <brief_title>VITARIA Registry Study</brief_title>
  <official_title>VITARIA Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will observe patients with symptomatic heart failure with implantable vagus
      nerve stimulation to provide insights into safety and efficacy during clinical routine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational prospective clinical registry in patients with symptomatic heart failure and
      implanted with the VITARIA System. Assessments will be made during 12 months of
      post-titration chronic stimulation. The registry will collect patient- and device follow-up
      data in clinical routine practice at baseline, 3, 6 and 12 months. Clinical routine safety of
      the therapy will be assessed by the incidence of procedure and device-related events.
      Clinical routine efficacy will be assessed by changes in cardiac function and heart failure
      symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Serious and non-serious adverse events, according to ISO 14155</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LVEF</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular ejection fraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LVESV</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular end-systolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESV Index</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular end-systolic volume index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>12 months</time_frame>
    <description>New York Heart Association classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Mean heart rate, 24-hour ambulatory ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>12 months</time_frame>
    <description>SDNN, 24-hour ambulatory ECG</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <description>Heart failure patients implanted with the VITARIA system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VITARIA System</intervention_name>
    <description>Implantable vagus nerve stimulator</description>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic heart failure, NYHA class II/III with LVEF≤40%
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and capable of providing informed consent according to national data privacy
             regulations

          2. Patients with NYHA class II/III

          3. LVEF≤40% by imaging method such as echocardiography, radionuclide angiography, left
             ventriculography, or cardiac magnetic resonance imaging, documented less than 12 weeks
             before implantation of VITARIA system

          4. Receiving optimal pharmacological heart failure therapy for at least 3 months

          5. Recent implantation of the VITARIA system, prior to device activation

        Exclusion Criteria:

          1. Hospitalization for heart failure and/or required the use of Heart Failure intravenous
             therapy in the past 30 days

          2. Severe mitral and/or any aortic valve dysfunction

          3. History of acute coronary syndrome (ACS) in the past 90 days

          4. Stroke or transient ischemic attack (TIA) in the past 90 days

          5. Coronary Artery Bypass Surgery (CABG) in the past 90 days

          6. PCI in the past 90 days

          7. Surgery for Valve replacement (Aortic or mitral valve) in the past 90 days

          8. Left ventricular end diastolic diameter (LVEDD) &gt; 80 mm

          9. Patients who have had a cardiac resynchronization therapy (CRT) device implanted and
             have been actively treated with CRT for &lt; 12 months

         10. Patients that are scheduled for CRT

         11. Patients who are listed for heart transplant or expected to be candidates for heart
             transplant

         12. Patients on hemodialysis or peritoneal dialysis

         13. Patients with diabetes (type I or type II) that is being medically treated for
             autonomic or sensory neuropathy, or measured hemoglobin A1c (HbA1c) above 8.0% in the
             past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRI GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI GmbH</name>
      <address>
        <city>Munich</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

